Why is Kimia Bioscien. falling/rising?

Stock Performance Against Benchmarks

Kimia Biosciences has underperformed markedly compared to the broader market indices over multiple time horizons. Over the past week, the stock declined by 7.59%, while the Sensex gained 0.79%. This negative trend extends over longer periods, with the stock falling 8.83% in the last month and a steep 30.59% over the past year, contrasting sharply with the Sensex’s 10.47% gain during the same period. Even over three and five years, the stock has lagged significantly, registering losses of 19.88% and 26.81% respectively, while the Sensex surged by 39.39% and 94.23%. These figures underscore persistent underperformance and investor caution surrounding the company.

Intraday Volatility and Trading Patterns

On 21-Nov, Kimia Biosciences exhibited high intraday volatility of 5.71%, with the stock price oscillating between a low of ₹31.20 and a high of ₹34.99. Despite touching an intraday high that represented a 2.61% gain, the weighted average price skewed closer to the day’s low, indicating heavier trading volume near the lower price levels. This pattern suggests selling pressure dominated the session. Additionally, the stock traded below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—signalling a bearish technical outlook. Investor participation also declined sharply, with delivery volumes on 20-Nov falling by nearly 87% compared to the five-day average, reflecting reduced confidence and liquidity concerns.

Fundamental Challenges Weighing on the Stock

Despite an attractive Return on Capital Employed (ROCE) of 31.1% and a low PEG ratio of 0.1, Kimia Biosciences faces significant headwinds. The company’s net sales have grown at a modest annual rate of 2.55% over the past five years, while operating profit has increased by 18.34%, indicating sluggish top-line and margin expansion. More concerning is the company’s high leverage, with an average debt-to-equity ratio of 14.13 times, which raises questions about financial stability and risk. The average ROCE of 9.76% over the long term further highlights limited profitability relative to the capital employed, signalling inefficiencies in generating returns for shareholders.

Recent Financial Results Disappoint

The latest six-month period ending September 2025 revealed a sharp decline in profitability, with the Profit After Tax (PAT) falling by 46.89% to ₹1.62 crore. Quarterly earnings before depreciation, interest, and taxes (PBDIT) stood at a low ₹2.52 crore, and the operating profit margin contracted to 7.41%, the lowest in recent quarters. These flat and weakening results have contributed to the negative market sentiment and the stock’s underperformance relative to the BSE500 index over the last three years, one year, and three months.

Investor Sentiment and Outlook

Investor confidence in Kimia Biosciences appears subdued, as reflected by the declining delivery volumes and the stock’s consistent underperformance against sector and market benchmarks. While the stock trades at a discount relative to peers’ historical valuations, the combination of high debt, weak long-term growth, and disappointing recent earnings results has overshadowed these positives. The majority shareholding by promoters does not seem to have provided sufficient reassurance to the market amid these challenges.

In summary, the decline in Kimia Biosciences’ share price on 21-Nov is primarily driven by its weak financial fundamentals, high leverage, and poor recent earnings performance. These factors have led to diminished investor participation and heightened volatility, resulting in the stock trading below key technical levels and underperforming the broader market indices.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →